Stock listing
NASDAQ:CELZ Creative Medical Technology Holdings, Inc. Stock
Home listing (NASDAQ) of Creative Medical Technology Holdings, Inc.
Follow Creative Medical Technology Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CELZ
$0.403 USD -0.064 (-13.7%)
Close on Nov 20, 2026
- Day range
- $0.400 – $0.433 USDNov 20, 2026
- Volume
- 74,892 sharesNov 20, 2026
- Market cap
- $3.06M USDAt the close on Nov 20, 2026 · price × 7.60M shares outstanding
- 52-week range
- $0.400 – $4.720 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $669,315 USDMedian day 118,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CELZ · Home | $0.403 USD | -0.064 (-13.7%) | 74,892 | $0.433 | $0.433 | $0.400 | $0.466 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CELZ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.403 | -0.064 | -13.7% | $0.433 | $0.433 | $0.400 | 74,892 | |
| $0.466 | -0.010 | -2.2% | $0.479 | $0.511 | $0.450 | 40,099 | |
| $0.477 | -0.043 | -8.4% | $0.523 | $0.523 | $0.461 | 86,686 | |
| $0.520 | -0.008 | -1.5% | $0.525 | $0.562 | $0.520 | 88,880 | |
| $0.528 | -0.089 | -14.4% | $0.615 | $0.623 | $0.528 | 152,703 | |
| $0.617 | -0.013 | -2.1% | $0.630 | $0.640 | $0.613 | 56,277 | |
| $0.630 | +0.029 | +4.7% | $0.600 | $0.649 | $0.600 | 43,158 | |
| $0.601 | -0.011 | -1.8% | $0.610 | $0.648 | $0.600 | 34,645 | |
| $0.612 | -0.010 | -1.6% | $0.613 | $0.635 | $0.600 | 104,349 | |
| $0.622 | +0.016 | +2.7% | $0.600 | $0.639 | $0.595 | 101,317 | |
| $0.606 | -0.046 | -7.1% | $0.700 | $0.700 | $0.590 | 123,524 | |
| $0.652 | -0.022 | -3.2% | $0.674 | $0.707 | $0.622 | 58,795 | |
| $0.674 | +0.050 | +8.0% | $0.645 | $0.674 | $0.630 | 116,508 | |
| $0.624 | -0.031 | -4.8% | $0.650 | $0.674 | $0.601 | 224,680 | |
| $0.655 | -0.023 | -3.4% | $0.719 | $0.719 | $0.655 | 86,506 | |
| $0.678 | -0.042 | -5.8% | $0.723 | $0.738 | $0.678 | 62,355 | |
| $0.720 | +0.030 | +4.3% | $0.693 | $0.720 | $0.672 | 90,483 | |
| $0.690 | -0.022 | -3.1% | $0.735 | $0.735 | $0.681 | 142,117 | |
| $0.712 | -0.028 | -3.8% | $0.765 | $0.765 | $0.710 | 44,896 | |
| $0.740 | -0.034 | -4.4% | $0.765 | $0.768 | $0.731 | 24,500 | |
| $0.774 | +0.032 | +4.3% | $0.754 | $0.780 | $0.740 | 46,000 | |
| $0.742 | -0.012 | -1.6% | $0.750 | $0.765 | $0.730 | 50,700 | |
| $0.755 | +0.031 | +4.3% | $0.702 | $0.780 | $0.680 | 404,900 | |
| $0.724 | -0.017 | -2.3% | $0.747 | $0.747 | $0.722 | 95,400 | |
| $0.741 | -0.077 | -9.4% | $0.839 | $0.849 | $0.734 | 168,800 | |
| $0.818 | +0.045 | +5.9% | $0.780 | $0.821 | $0.763 | 63,100 | |
| $0.772 | -0.048 | -5.8% | $0.800 | $0.800 | $0.757 | 167,400 | |
| $0.820 | -0.021 | -2.5% | $0.830 | $0.850 | $0.810 | 56,900 | |
| $0.841 | +0.002 | +0.3% | $0.830 | $0.869 | $0.822 | 90,100 | |
| $0.839 | -0.022 | -2.5% | $0.860 | $0.880 | $0.820 | 148,800 | |
| $0.860 | -0.029 | -3.2% | $0.880 | $0.893 | $0.860 | 40,300 | |
| $0.889 | -0.011 | -1.3% | $0.910 | $0.910 | $0.880 | 52,200 | |
| $0.900 | -0.020 | -2.1% | $0.900 | $0.918 | $0.890 | 70,100 | |
| $0.920 | -0.026 | -2.8% | $0.960 | $0.960 | $0.920 | 70,900 | |
| $0.946 | +0.005 | +0.5% | $0.940 | $0.970 | $0.915 | 89,500 | |
| $0.942 | +0.007 | +0.8% | $0.930 | $0.970 | $0.930 | 208,300 | |
| $0.935 | -0.031 | -3.2% | $0.930 | $0.980 | $0.882 | 98,100 | |
| $0.965 | -0.045 | -4.4% | $1.000 | $1.011 | $0.910 | 234,800 | |
| $1.010 | -0.020 | -1.9% | $1.000 | $1.040 | $0.980 | 213,800 | |
| $1.030 | +0.060 | +6.2% | $0.990 | $1.050 | $0.942 | 321,500 | |
| $0.970 | -0.004 | -0.4% | $0.948 | $0.990 | $0.920 | 200,700 | |
| $0.974 | +0.034 | +3.6% | $0.891 | $1.000 | $0.891 | 361,200 | |
| $0.940 | -0.065 | -6.5% | $0.880 | $0.960 | $0.800 | 1,778,700 | |
| $1.005 | +0.039 | +4.0% | $0.993 | $1.040 | $0.947 | 20,008,800 | |
| $0.966 | +0.088 | +10.1% | $0.889 | $0.966 | $0.874 | 167,800 | |
| $0.878 | +0.055 | +6.8% | $0.860 | $0.897 | $0.829 | 180,000 | |
| $0.822 | -0.063 | -7.1% | $0.894 | $0.900 | $0.821 | 146,600 | |
| $0.885 | +0.007 | +0.8% | $0.917 | $0.972 | $0.850 | 118,800 | |
| $0.878 | -0.083 | -8.6% | $0.951 | $0.973 | $0.856 | 404,200 | |
| $0.961 | +0.010 | +1.1% | $0.950 | $0.998 | $0.950 | 99,700 | |
| $0.950 | -0.090 | -8.6% | $1.050 | $1.056 | $0.936 | 320,300 | |
| $1.040 | -0.040 | -3.7% | $1.080 | $1.085 | $1.040 | 109,000 | |
| $1.080 | -0.030 | -2.7% | $1.100 | $1.120 | $1.070 | 140,500 | |
| $1.110 | +0.050 | +4.7% | $1.060 | $1.120 | $1.060 | 151,200 | |
| $1.060 | -0.070 | -6.2% | $1.140 | $1.140 | $1.040 | 173,100 | |
| $1.130 | +0.030 | +2.7% | $1.100 | $1.150 | $1.100 | 94,100 | |
| $1.100 | -0.030 | -2.7% | $1.110 | $1.130 | $1.090 | 104,900 | |
| $1.130 | -0.010 | -0.9% | $1.140 | $1.190 | $1.090 | 243,200 | |
| $1.140 | 0.000 | 0.0% | $1.170 | $1.180 | $1.115 | 197,500 | |
| $1.140 | -0.050 | -4.2% | $1.200 | $1.210 | $1.120 | 248,900 | |
| $1.190 | -0.050 | -4.0% | $1.220 | $1.250 | $1.190 | 249,100 | |
| $1.240 | +0.030 | +2.5% | $1.190 | $1.260 | $1.190 | 171,193 | |
| $1.210 | -0.100 | -7.6% | $1.290 | $1.290 | $1.190 | 387,166 | |
| $1.310 | +0.030 | +2.3% | $1.270 | $1.350 | $1.220 | 545,100 | |
| $1.280 | +0.160 | +14.3% | $1.280 | $1.430 | $1.080 | 10,263,400 |
Splits
3 splits since 2020 · NASDAQ:CELZ · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-500 | Consolidation | |
| 1-for-150 | Consolidation |
- Ticker
- NASDAQ:CELZ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
Oct 20, 2026
Closed $0.755 (+4.3%) on Oct 20, 2026
Creative Medical Technology Holdings, Inc. Expands Ultrasome Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Sep 18, 2026
Closed $0.966 (+10.1%) on Sep 18, 2026
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Aug 20, 2026
Closed $1.28 (+14.3%) on Aug 20, 2026
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Aug 6, 2026
Closed $1.15 (+71.9%) on Aug 6, 2026
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
Jun 30, 2026
Closed $1.45 (+79.0%) on Jun 30, 2026
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Jun 22, 2026
Closed $1.93 (-13.5%) on Jun 22, 2026
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
Jun 16, 2026
Closed $2.24 (-6.3%) on Jun 16, 2026
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Apr 28, 2026
Closed $2.23 (-2.2%) on Apr 28, 2026
Creative Medical Technology Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 99 in all · newest Oct 20, 2026 · oldest 2020
Where Creative Medical Technology Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CELZ · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CELZ | BOATS | United States | USD |
Valuation
EV/sales −1,263× against a median of 5.6×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.79M USD
- P/E
- Loss
- EV/sales
- −1,263×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- 66.9%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.53
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Creative Medical Technology Holdings, Inc. · NASDAQ:CELZ | US$3.06M | −US$3.79M | n/a | −1,263× | n/a | 0.4× | n/a | 0.0× | 1.53 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,074 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.39M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Oncology Pharma Inc. · OTC:ONPH | US$3.04M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.62 |
| Imunon, Inc. · NASDAQ:IMNN | US$3.00M | US$5.90M | n/a | n/a | n/a | 1.1× | n/a | 2.6× | 0.57 |
| Gelteq Limited · NASDAQ:GELS | US$2.89M | US$6.28M | n/a | 57.1× | n/a | 0.3× | n/a | 0.4× | 0.83 |
| Median of the others | US$3.11M | −US$618,677 | 5.6× | 0.5× | 0.0× | 0.83 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.18 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Timothy Warbington | CEO & Co-Founder |
| Donald Dickerson | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Bruce S. Urdang | Board Member |
| Mike Finger | Board Member |
| Susan Snow | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · After close | −1.6% |
| Q2 2026 | Aug 7, 2026 | +4.3% |
| Q1 2026 | May 8, 2026 · After close | −5.6% |
| Q4 2025 | Feb 25, 2026 | +1.7% |
| Q3 2025 | Nov 7, 2025 · After close | +8.6% |
| Q2 2025 | Aug 8, 2025 · After close | −12.3% |
| Q1 2025 | May 9, 2025 · After close | −7.5% |
| Q4 2024 | Mar 20, 2025 · After close | +3.6% |
| Q3 2024 | Nov 8, 2024 · After close | +3.2% |
| Q2 2024 | Aug 9, 2024 · After close | +16.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | −0.5% |
| Q4 2023 | Mar 22, 2024 · After close | +4.4% |
| Q3 2023 | Nov 14, 2023 · After close | +4.3% |
| Q2 2023 | Aug 11, 2023 · After close | +0.8% |
| Q1 2023 | May 12, 2023 · After close | 0.0% |
| Q4 2022 | Mar 31, 2023 · After close | −0.6% |
| Q3 2022 | Nov 10, 2022 · After close | −1.2% |
| Q2 2022 | Aug 12, 2022 · After close | −2.1% |
| Q1 2022 | May 13, 2022 · After close | −8.7% |
| Q4 2021 | Mar 30, 2022 · After close | +15.0% |
Financings
| Raise | Date |
|---|---|
| Warrant exercise of existing warrants exercised for common stock Announced: about US$4.5M · US$1.6 a share · Warrants at US$1.6 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital and general corporate purposes | Jun 30, 2026 |
| Warrant exercise of common shares on exercise of existing warrants Announced: about US$4.2M · US$3.75 a share · Warrants at US$3.75 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital and general corporate purposes | Oct 29, 2025 |
| Warrant exercise of existing warrants to purchase common stock Announced: about US$3.7M · US$4.42 a share · Warrants at US$3.75 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital and general corporate purposes | Mar 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.00K | 11.0K | 9.00K | 88.6K | 87.8K | 164.5K | 165.5K | 124.4K | 4.80K | 0 |
| Cost of revenue | 2.19K | 4.40K | 3.60K | 28.5K | 47.9K | 50.6K | 45.5K | 70.4K | 8.00K | 0 |
| Gross profit | 3.81K | 6.60K | 5.40K | 60.1K | 39.8K | 113.9K | 120.0K | 54.0K | -3.20K | 0 |
| Research and development | 2.26M | 2.40M | 1.97M | 6.27M | 109.2K | 0 | 0 | 96.6K | 260.1K | 85.3K |
| Selling, general and administrative | 3.76M | 3.24M | 3.56M | 3.94M | 2.96M | 1.16M | 1.22M | 1.05M | 898.5K | 665.0K |
| Operating income | -6.14M | -5.74M | -5.62M | -10.2M | -3.13M | -1.11M | -1.13M | -1.11M | -1.18M | -759.7K |
| Depreciation and amortization | 123.3K | 56.0K | 56.0K | 92.1K | 92.1K | 66.8K | 26.9K | 21.1K | 16.0K | 9.36K |
| EBITDA | -6.02M | -5.69M | -5.56M | -10.2M | -3.03M | -1.05M | -1.10M | -1.09M | -1.16M | -750.3K |
| Interest expense | 0 | 4.28M | 1.23M | 1.90M | 1.36M | 377.6K | 6.40K | |||
| Income before tax | -6.00M | -5.49M | -5.29M | -10.1M | 19.2M | -36.3M | -8.48M | -13.7M | -2.66M | -766.1K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -6.00M | -5.49M | -5.29M | -10.1M | 19.2M | -36.3M | -8.48M | -13.7M | -2.66M | -766.1K |
| Earnings per share, basic | -1.62 | -3.14 | -3.85 | -0.93 | 7.37 | -62.69 | -0.82 | -3.50 | -0.03 | -0.01 |
| Earnings per share, diluted | -2.52 | -3.71 | -3.76 | -0.93 | 5.61 | -62.69 | -0.82 | -3.50 | -0.03 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.21M | 5.94M | 3.47M | 8.32M | 10.7M | 98.0K | 88.6K | 304.1K | 13.7K | 221.9K |
| Short-term investments | 0 | 6.52M | 10.1M | 0 | ||||||
| Receivables | 52.1K | 0 | 2.48K | 0 | 5.60K | 9.60K | 4.80K | 0 | ||
| Inventory | 0 | 2.19K | 6.59K | 10.2K | 10.9K | 0 | 0 | |||
| Current assets | 7.40M | 6.14M | 10.3M | 18.7M | 10.7M | 98.0K | 94.2K | 313.7K | 18.5K | 221.9K |
| Total assets | 7.81M | 6.67M | 10.7M | 19.2M | 11.3M | 717.8K | 530.8K | 477.2K | 203.1K | 322.5K |
| Accounts payable | 270.7K | 273.5K | 317.3K | 3.27M | 761.9K | 350.9K | 320.8K | 331.8K | 237.6K | 66.4K |
| Current liabilities | 284.9K | 327.6K | 371.4K | 3.32M | 1.05M | 40.5M | 8.60M | 4.47M | 2.44M | 453.9K |
| Long-term debt | 915 | 25.0K | ||||||||
| Total debt | 14.2K | 14.2K | 14.2K | 14.2K | 14.2K | 788.7K | 1.06M | 682.1K | 493.3K | 125.0K |
| Total liabilities | 284.9K | 327.6K | 371.4K | 3.32M | 1.05M | 40.5M | 8.60M | 4.47M | 2.44M | 480.3K |
| Shareholders' equity | 7.51M | 6.34M | 10.3M | 15.9M | 10.2M | -39.8M | -8.07M | -3.99M | -2.24M | -157.8K |
| Shares outstanding | 3.70M | 1.75M | 1.37M | 1.41M | 6.34M | 1.54M | 22.5M | 6.02M | 114.8M | 105.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.86M | -5.30M | -8.03M | -7.80M | -2.22M | -434.6K | -1.21M | -1.05M | -889.6K | -445.2K |
| Capital spending | -5 | -200.0K | -100.0K | -4 | 0 | -250.0K | -3 | 0 | 0 | -10.0K |
| Free cash flow | -5.86M | -5.30M | -8.13M | -7.80M | -2.22M | -684.6K | -1.21M | -1.05M | -889.6K | -455.2K |
| Cash from investing | -50.5K | 6.32M | 3.45M | -10.1M | 0 | -250.0K | 0 | -250.0K | 0 | -10.0K |
| Cash from financing | 7.17M | 1.45M | -271.0K | 15.5M | 12.8M | 693.9K | 997.7K | 1.34M | 681.5K | 677.0K |
| Dividends paid | -4.78M | |||||||||
| Share buybacks | -10.0K | -175.0K | -271.0K | 0 | -196.8K | 0 | 100.0K | 100.0K | ||
| Change in cash | 1.27M | 2.47M | -4.85M | -2.40M | 10.6M | 9.36K | -215.4K | 290.4K | -208.2K | 221.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Nov 10, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 31, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | Aug 3, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 3, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Jul 24, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Jul 14, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 2, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Jul 1, 2026 | Meeting notice | SEC |
| RW · Request to withdraw a registration | Jun 30, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 26, 2026 | Offer document | SEC |
| S-1 · Registration statement | Jun 25, 2026 | Offer document | SEC |
| DRS · Draft registration statement | May 28, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 24, 2026 | Annual report | SEC |
| 10-K · Annual report | Mar 20, 2026 | Annual report | SEC |
| 8-K · Current report | Dec 31, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Dec 19, 2025 | Meeting outcome | SEC |
| 424B3 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Nov 13, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Nov 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 31, 2025 | Material contract | SEC |
| DEF 14A · Proxy statement | Oct 30, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Meeting outcome | SEC |
| 10-K/A · Annual report, amended | Apr 25, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 14, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 9, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2025 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 4, 2025 | Annual report | SEC |
| S-3 · Registration statement | Apr 2, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Mar 19, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 17, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 14, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 14, 2025 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 7, 2025 | Material contract | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 26, 2024 | Meeting outcome | SEC |
| 424B3 · Prospectus | Nov 20, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 20, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| S-1 · Registration statement | Nov 8, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Nov 4, 2024 | Meeting notice | SEC |
| PRER14A | Oct 23, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 23, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 23, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 10, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Oct 4, 2024 | Meeting notice | SEC |
| S-3 · Registration statement | Oct 4, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 25, 2024 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jun 5, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 17, 2024 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | May 17, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 10-K · Annual report | Mar 22, 2024 | Annual report | SEC |
| 8-K · Current report | Dec 20, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Nov 3, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 29, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 28, 2023 | Current report | SEC |
| 8-K · Current report | Jun 9, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | May 26, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| SC 13G · Big-stake notice | May 1, 2023 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | May 1, 2023 | Annual report | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Dec 19, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 23, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Oct 26, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jul 14, 2022 | Current report | SEC |
| 4 · Change in ownership | Jun 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2022 | Insider trade | SEC |
| 424B3 · Prospectus | May 20, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 20, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 17, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 16, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | May 13, 2022 | Quarterly report | SEC |
| S-3 · Registration statement | May 10, 2022 | Offer document | SEC |
| D | May 5, 2022 | Other filings | SEC |
| RW · Request to withdraw a registration | May 4, 2022 | Other filings | SEC |
| 8-K · Current report | May 4, 2022 | Material contract | SEC |
| 8-K · Current report | May 4, 2022 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2022 | Annual report | SEC |
| S-1 · Registration statement | Apr 22, 2022 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2022 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2022 | Insider trade | SEC |
| 8-K · Current report | Feb 11, 2022 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jan 5, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Dec 17, 2021 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Dec 13, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 13, 2021 | Insider trade | SEC |
| SC 13G · Big-stake notice | Dec 10, 2021 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Dec 8, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Dec 7, 2021 | Material contract | SEC |
| 424B4 · Prospectus | Dec 6, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 3, 2021 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Dec 2, 2021 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Dec 2, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 2, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 2, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 2, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 1, 2021 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 30, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 30, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 23, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 23, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 15, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2021 | Current report | SEC |
| 8-K · Current report | Nov 5, 2021 | Current report | SEC |
| UPLOAD · Letter from the SEC | Oct 7, 2021 | Other filings | SEC |
| S-1 · Registration statement | Sep 27, 2021 | Offer document | SEC |
| DEF 14C | Sep 24, 2021 | Meeting notice | SEC |
| 8-K · Current report | Sep 22, 2021 | Management or board change | SEC |
| PRE 14C | Sep 7, 2021 | Meeting notice | SEC |
| D | Aug 27, 2021 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 16, 2021 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2021 | Material contract | SEC |
| 4 · Change in ownership | Jul 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | May 17, 2021 | Quarterly report | SEC |
| 8-K · Current report | Apr 2, 2021 | Material contract | SEC |
| 8-K · Current report | Mar 25, 2021 | Current report | SEC |
| 10-K · Annual report | Mar 17, 2021 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2021 | Current report | SEC |
| 8-K · Current report | Mar 5, 2021 | Current report | SEC |
| 8-K · Current report | Feb 22, 2021 | Current report | SEC |
| 8-K/A · Current report, amended | Feb 22, 2021 | Material contract | SEC |
| 8-K · Current report | Feb 18, 2021 | Material contract | SEC |
| 8-K · Current report | Feb 12, 2021 | Current report | SEC |
| 8-K · Current report | Feb 8, 2021 | Current report | SEC |
| 8-K · Current report | Jan 14, 2021 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2021 | Insider trade | SEC |
| 8-K · Current report | Jan 4, 2021 | Current report | SEC |
| 4 · Change in ownership | Dec 31, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2020 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2020 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 5, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2020 | Quarterly report | SEC |
| 10-K · Annual report | Apr 6, 2020 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 30, 2020 | Explanation request | SEC |
| 8-K · Current report | Mar 24, 2020 | Current report | SEC |
| 4 · Change in ownership | Feb 19, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2020 | Insider trade | SEC |
| 8-K · Current report | Jan 31, 2020 | Current report | SEC |
| DEFR14C | Jan 3, 2020 | Other filings | SEC |
| 4 · Change in ownership | Dec 13, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2019 | Insider trade | SEC |
| DEF 14C | Nov 22, 2019 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2019 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2019 | Insider trade | SEC |
| PRE 14C | Nov 5, 2019 | Meeting notice | SEC |
| 8-K · Current report | Oct 16, 2019 | Material contract | SEC |
| DEF 14C | Sep 13, 2019 | Meeting notice | SEC |
| 8-K · Current report | Sep 9, 2019 | Current report | SEC |
| PRE 14C | Aug 30, 2019 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2019 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2019 | Material contract | SEC |
This page holds 200 of 412 filings. Open Filings
Cap table
Built by 6ix from Creative Medical Technology Holdings, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 7,597,557
- Fully diluted
- 7,597,557
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 7,597,557 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 7,597,557 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Susan Snow Other companies: NeoVolta Inc. (Director · Since at least Jul 27, 2022); Basin Water Inc (Director · May 6, 2008 – May 6, 2008 · Past) | Board Member · Since at least Dec 2, 2021 |
| Thomas Ichim Other companies: Therapeutic Solutions International, Inc. (Director · Oct 18, 2016 – Oct 1, 2024 · Past) | Director · May 18, 2016 – Jul 20, 2021 · Past |
| Amit Nilkanth Patel | Director · May 18, 2016 – Jul 15, 2021 · Past |
| Bruce S. Urdang | Board Member · Since at least Dec 2, 2021 |
| Courtney Bartlett | Director of Clinical Development · Feb 20, 2025 – Nov 4, 2026 · Past |
| Donald Dickerson | Chief Financial Officer · Since at least May 18, 2016 |
| Mike Finger | Board Member · Since at least Dec 2, 2021 |
| Steven L White | President, Director · Jan 20, 2009 – May 18, 2016 · Past |
| Timothy Warbington | CEO & Co-Founder · Since at least May 18, 2016 |
Log in to ask 6ix AI your own questions about Creative Medical Technology Holdings, Inc.